Why Bay Area's XOMA Surged 700% in 2017 by Not Making Drugs Post author:Sam Post published:January 25, 2018 Post category:BioPharma The company burned through $1.2B and never brought a drug to market in its 37 years. Source: BioSpace You Might Also Like Sarepta Under Pressure As Marathon Pharma Emflaza's Wins FDA Approval for DMD February 9, 2017 Why This Massachusetts Synthetic Bio Startup Could be the Next Biotech Unicorn December 11, 2017 Rumor Alert: AstraZeneca PLC CEO to Become Teva's New Leader July 12, 2017
